Ozempic costs ~$42/month on PBS for diabetes. Wegovy costs $350–$450 privately. Full comparison of costs, PBS coverage, who qualifies, and which is right for you.
Download on the App StoreFor type 2 diabetes patients on a PBS prescription, dramatically so — approximately $42 per month versus $350–$450 for Wegovy. For weight loss patients using semaglutide privately without a diabetes diagnosis, the costs are broadly similar.
Both contain semaglutide. Ozempic is approved for type 2 diabetes and PBS-listed at up to 2mg weekly. Wegovy is approved for weight management and private-only at up to 2.4mg weekly. The higher dose in Wegovy is what makes it more effective for weight loss specifically.
Wegovy is not PBS-listed for weight loss, so there is no government subsidy. Ozempic's low cost for diabetes patients comes from the PBS, not because the drug itself is cheaper to produce.
Ozempic is sometimes prescribed off-label for weight loss, but as a private prescription — no PBS subsidy applies and the cost is similar to Wegovy. There have also been Ozempic shortages in Australia due to weight loss demand competing with diabetes supply. Your prescriber can advise on the best option for your situation.
PBS listing of semaglutide for weight management would lower costs significantly for eligible patients. As of mid-2026 no such listing has been approved, though it remains under active policy discussion in Australia.
Both contain semaglutide. The higher maximum dose in Wegovy (2.4mg vs 2mg for Ozempic) is associated with greater average weight loss in clinical studies. However, individual responses vary and your prescriber is best placed to recommend based on your health profile.
Mounjaro (tirzepatide) has shown greater average weight loss than semaglutide in head-to-head trials. It is available in Australia on private prescription at broadly comparable pricing to Wegovy. PBS listing for weight management is under review.